×
ADVERTISEMENT

Yervoy, Bristol-Myers Squibb

Study Supports Nivo-Ipi Combo Over Monotherapy for mRCC

The combination of nivolumab and ipilimumab may be more effective for treating metastatic renal cell carcinoma ...

AUGUST 17, 2017

Yervoy Approved for Pts 12 and Older With Unresectable or Metastatic Melanoma

The FDA approved impilimumab for pediatric patients 12 years and older with unresectable or metastatic melanoma.

JULY 25, 2017

Load more